Puriblood Medical Co., Ltd.
Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan. The company offers leukoreduction, cell separation, and P-Tex, an advanced anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsi… Read more
Puriblood Medical Co., Ltd. (6847) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.073x
Based on the latest financial reports, Puriblood Medical Co., Ltd. (6847) has a cash flow conversion efficiency ratio of -0.073x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-11.92 Million) by net assets (NT$163.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Puriblood Medical Co., Ltd. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Puriblood Medical Co., Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Puriblood Medical Co., Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Puriblood Medical Co., Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CUE Energy Resources Ltd
AU:CUE
|
0.154x |
|
Kalaris Therapeutics, Inc.
NASDAQ:KLRS
|
-0.271x |
|
Kentucky First Federal Bancorp
NASDAQ:KFFB
|
-0.006x |
|
Greenwood Sejahtera Tbk
JK:GWSA
|
0.004x |
|
Agung Semesta Sejahtera Tbk PT
JK:TARA
|
-0.002x |
|
United Homes Group Inc.
NASDAQ:UHG
|
-0.449x |
|
Thermal Energy International Inc
OTCQB:TMGEF
|
-0.409x |
|
Secuve Co. Ltd
KQ:131090
|
0.022x |
Annual Cash Flow Conversion Efficiency for Puriblood Medical Co., Ltd. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Puriblood Medical Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$175.40 Million | NT$-29.68 Million | -0.169x | -215.04% |
| 2023-12-31 | NT$181.16 Million | NT$26.64 Million | 0.147x | +211.16% |
| 2022-12-31 | NT$233.03 Million | NT$-30.83 Million | -0.132x | +34.42% |
| 2021-12-31 | NT$216.50 Million | NT$-43.68 Million | -0.202x | -202.34% |
| 2020-12-31 | NT$144.17 Million | NT$-9.62 Million | -0.067x | +88.57% |
| 2019-12-31 | NT$26.62 Million | NT$-15.54 Million | -0.584x | -- |